Pharmacodynamic genes do not influence risk of neutropenia in cancer patients treated with moderately high-dose irinotecan

Pharmacogenomics

Volumn 10, Issue 7, 2009, Pages 1139-1146

  Hoskins, Janelle M ^a   Rosner, Gary L ^b   Ratain, Mark J ^c   McLeod, Howard L ^a   Innocenti, Federico ^c  

^a University of North Carolina   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

Irinotecan; PARP1; Pharmacogenetics; TDP1; TOP1; XRCC1

Indexed keywords

DNA; DNA TOPOISOMERASE; IRINOTECAN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PHOSPHODIESTERASE; TYROSYL DNA PHOSPHODIESTERASE; UNCLASSIFIED DRUG; XRCC1 PROTEIN;

ADULT; AGED; ARTICLE; CANCER PATIENT; CONTINUOUS INFUSION; CONTROLLED STUDY; DNA ISOLATION; DRUG EFFICACY; FEMALE; GENE DELETION; GENE FREQUENCY; GENE INSERTION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; HUMAN CELL; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NEUTROPHIL COUNT; POLYMERASE CHAIN REACTION; PREDICTION; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; CAMPTOTHECIN; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HAPLOTYPES; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; NEUTROPENIA; POLYMORPHISM, GENETIC; RISK FACTORS;

EID: 70449513131     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.09.35     Document Type: Article

References (28)

1. Douillard JY, Cunningham D, Roth AD et al.: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355, 1041-1047 (2000). (Pubitemid 30162806)
2. Saltz LB, Cox JV, Blanke C et al.; Irinotecan Study Group: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 343, 905-914 (2000). (Pubitemid 30727802)
3. Hurwitz H, Fehrenbacher L, Novotny W et al.: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350, 2335-2342 (2004). (Pubitemid 38702844)
4. Vincenzi B, Santini D, Rabitti C et al.: Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: a single centre Phase II trial. Br. J. Cancer 94, 792-797 (2006).
5. Innocenti F, Ratain MJ: Pharmacogenetics of irinotecan: clinical perspectives on the utility of genotyping. Pharmacogenomics 7, 1211-1221 (2006).
6. Marsh S, McLeod HL: Pharmacogenetics of irinotecan toxicity. Pharmacogenomics 5, 835-843 (2004). (Pubitemid 39386752)
7. Smith NF, Figg WD, Sparreboom A: Pharmacogenetics of irinotecan metabolism and transport: an update. Toxicol. In Vitro 20, 163-175 (2006).
8. Beutler E, Gelbart T, Demina A: Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc. Natl Acad. Sci. USA 95, 8170-8174 (1998). (Pubitemid 28326085)
9. Ando Y, Saka H, Ando M et al.: Polymorphisms of UDP- glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic ana lysis. Cancer Res. 60, 6921-6926 (2000). (Pubitemid 32059164)
10. Innocenti F, Undevia SD, Iyer L et al.: Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J. Clin. Oncol. 22, 1382-1388 (2004). ■■ Phase I trial of advanced cancer patients treated with moderately high-dose single-agent irinotecan (350 mg/m2 every 21 days) showed that patients with the UGT1A1*28/*28 genotype had an elevated risk of severe neutropenia in cycle one.
11. Rouits E, Boisdron-Celle M, Dumont A, Guerin O, Morel A, Gamelin E: Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients. Clin. Cancer Res. 10, 5151-5159 (2004). (Pubitemid 39099790)
12. Marcuello E, Altes A, Menoyo A, Del Rio E, Gomez-Pardo M, Baiget M: UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer. Br. J. Cancer 91, 678-682 (2004). (Pubitemid 39141623)
13. Iyer L, Das S, Janisch L et al.: UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J. 2, 43-47 (2002). (Pubitemid 34982202)
14. Paoluzzi L, Singh AS, Price DK et al.: Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38. J. Clin. Pharmacol. 44, 854-860 (2004).
15. Hoskins JM, Goldberg RM, Qu P, Ibrahim JG, McLeod HL: UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. J. Natl Cancer Inst. 99, 1290-1295 (2007). ■■ Meta-ana lysis of irinotecan-UGT1A1*28 pharmacogenetic studies showed that the risk of hematological toxicity was higher among patients with a UGT1A1*28/*28 genotype than among other patients at both medium and high doses of irinotecan. However, risk was similar at lower doses.
16. Pommier Y, Pourquier P, Urasaki Y, Wu J, Laco GS: Topoisomerase inhibitors I: selectivity and cellular resistance. Drug Resist. Updat. 2, 307-318 (1999). (Pubitemid 30070455)
17. Rasheed ZA, Rubin EH: Mechanisms of resistance to topoisomerase I-targeting drugs. Oncogene 22, 7296-7304 (2003).
18. Barrows LR, Holden JA, Anderson M, D'Arpa P: The CHO XRCC1 mutant, EM9, deficient in DNA ligase III activity, exhibits hypersensitivity to camptothecin independent of DNA replication. Mutat. Res. 408, 103-110 (1998).
19. Park JY, Lee SY, Jeon HS et al.: Polymorphism of the DNA repair gene XRCC1 and risk of primary lung cancer. Cancer Epidemiol. Biomarkers Prev. 11, 23-27 (2002).
20. Malanga M, Althaus FR: Poly(ADP-ribose) reactivates stalled DNA topoisomerase I and induces DNA strand break resealing. J. Biol. Chem. 279, 5244-5248 (2004). (Pubitemid 38220543)
21. Barthelmes HU, Habermeyer M, Christensen MO et al.: TDP1 overexpression in human cells counteracts DNA damage mediated by topoisomerases I and II. J. Biol. Chem. 279, 55618-55625 (2004). (Pubitemid 40066566)
22. Pommier Y: Camptothecins and topoisomerase I: a foot in the door. Targeting the genome beyond topoisomerase I with camptothecins and novel anticancer drugs: importance of DNA replication, repair and cell cycle checkpoints. Curr. Med. Chem. Anticancer Agents 4, 429-434 (2004).
23. Hoskins JM, Marcuello E, Altes A et al.: Irinotecan pharmacogenetics: influence of pharmacodynamic genes. Clin. Cancer Res. 14, 1788-1796 (2008). ■ Retrospective study that used the same patient cohort as [12], found by multivariate analyses that XRCC1 diplotype was an independent predictor of objective response in advanced colorectal cancer patients receiving irinotecan-containing regimens.
24. Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA: Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am. J. Hum. Genet. 70, 425-434 (2002).
25. Lockett KL, Hall MC, Xu J et al.: The ADPRT V762A genetic variant contributes to prostate cancer susceptibility and deficient enzyme function. Cancer Res. 64, 6344-6348 (2004). (Pubitemid 39129440)
26. Zhang X, Miao X, Liang G et al.: Polymorphisms in DNA base excision repair genes ADPRT and XRCC1 and risk of lung cancer. Cancer Res. 65, 722-726 (2005). (Pubitemid 40216429)
27. Hu Z, Ma H, Chen F, Wei Q, Shen H: XRCC1 polymorphisms and cancer risk: a meta-ana lysis of 38 case-control studies. Cancer Epidemiol. Biomarkers Prev. 14, 1810-1818 (2005).
28. Hu Z, Ma H, Lu D et al.: A promoter polymorphism (-77T>C) of DNA repair gene XRCC1 is associated with risk of lung cancer in relation to tobacco smoking. Pharmacogenet. Genomics 15, 457-463 (2005). (Pubitemid 41017594)